Source: Eyewire News

Neurotech Pharmaceuticals, Inc.: Neurotech Receives Priority Review of BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)

The FDA has grated priority review of Neurotech Pharmaceuticals's biologic license application (BLA) for NT-501 (revakinagene taroretcel

Read full article »
Neurotech Pharmaceuticals, Inc.'s Competitors | Neurotech Pharmaceuticals, Inc.'s News | Neurotech Pharmaceuticals, Inc.'s Financials
Stay up-to-date with the latest news on Neurotech Pharmaceuticals, Inc.
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Richard Small's photo - CEO of Neurotech Pharmaceuticals, Inc.

CEO

Richard Small

CEO Approval Rating

86/100

Read more
Stay up-to-date with the latest news on Neurotech Pharmaceuticals, Inc.